Overactive Bladder Treatment Market to Witness Robust Growth in North America & Asia Pacific
Overactive bladder (OAB) is not a disease, it is a problem with bladder function that causes the sudden need to urinate. Diabetes, an enlarged prostate, and ageing are the major risk factors. Treatments such as pelvic floor muscle exercises, medication, and nerve stimulation can reduce or eliminate symptoms. Thus, with the increasing incidence of overactive bladder, worldwide, the demand for Overactive Bladder Treatment is also increasing. In October 2020, Zydus Cadila received final approval from the United States Food and Drug Administration (FDA) to market Solifenacin Succinate tablets, for the treatment of overactive bladder. The company received approval to market Solifenacin Succinate tablets, in the strengths of 5 mg and 10 mg. This in turn is expected to accelerate the growth of the Overactive Bladder Treatment market. Frequent urination and urine leakage are the main symptoms of overactive bladder. Frequent urination is common in such patients. Overactiv...